CompletedNot Applicable

TVMR With the Innovalve System Trial - First In Human Israel

Israel1 participantsStarted 2021-10-01

Plain-language summary

Study to evaluate the safety and performance of the Innovalve mitral valve replacement system

Who can participate

Age range18 Years

SexALL

See this in plain English?

AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.

Inclusion Criteria: * Clinically significant, symptomatic mitral regurgitation * High risk for open-heart surgery * Meets anatomical criteria Exclusion Criteria: * Unsuitable anatomy * Patient is inoperable * EF\<25%

What they're measuring

Absence of implant or delivery related serious adverse events at 30 days

Timeframe: 30 days

Trial details

NCT IDNCT05688514

SponsorEdwards Lifesciences

Sponsor typeINDUSTRY

Study typeINTERVENTIONAL

Primary completion2021-10-06

View on ClinicalTrials.gov More Mitral Valve Regurgitation (Degenerative or Functional) trials